Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CIITA |
| Gene Name: | CIITA |
| Protein Full Name: | MHC class II transactivator |
| Alias: | C2TA; class II, major histocompatibility complex, transactivator; MHC class II transactivator CIITA; MHC2TA; NLR family, acid domain containing; NLRA; nucleotide-binding oligomerization domain, leucine rich repeat and acid domain containing |
| Mass (Da): | 123443 |
| Number AA: | 1130 |
| UniProt ID: | P33076 |
| Locus ID: | 4261 |
| COSMIC ID: | CIITA |
| Gene location on chromosome: | 16p13 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19536 |
| Percent of cancer specimens with mutations: | 1.01 |
| Deregulated in translocations: | BCL6 |
| Normal role description: | CIITA is a transcriptional activator of MHC genes. It is induced by interferon-gamma. It uses GTP to translocates to the nucleus and has acetyltransferase activity to act as a coactivator for transcription regulation. It has been shown to actiave MHC class I and MHC class II as well as molecules associated with MHC class II. |